抗治療性憂鬱症市場：依藥物類型、通路和地區分類

Treatment Resistant Depression Market, By Drug Type, By Distribution Channel, By Geography

出版日期: 2024年06月06日 | 出版商:

Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2024年，抗治療性憂鬱症市場規模將達到19.1億美元，2024年至2031年的複合年成長率為4.2%，預計到2031年將達到25.4億美元。

圖 1. 2024 年抗治療性憂鬱症市場佔有率(%)，依地區分類

抗治療性憂鬱症(TRD) 是一種常見的精神疾病，患者對標準抗憂鬱症反應不充分。大約 30% 至 50% 的重度憂鬱症患者會出現 TRD。抗治療性的確切原因仍不清楚，但據認為與生物和環境因素有關，例如遺傳和神經系統變化。 TRD 患者會經歷更嚴重的憂鬱症症狀，包括無價值感、極度悲傷、疲勞和對日常生活失去興趣，這損害了他們的生活品質。如果不及時治療，TRD 會增加殘疾、功能障礙和自殺的風險。抗治療性憂鬱症市場包括旨在為抗憂鬱症無反應的患者提供替代治療選擇的治療方法方法。

市場動態：

全球抗治療性憂鬱症市場的成長是由全球 TRD 盛行率不斷上升所推動的。據估計，超過 30% 的重度憂鬱症患者在一線抗憂鬱症治療後並未獲得緩解。這種反應遲鈍會導致長期的痛苦和增加的經濟負擔。市場也受益於 TRD 診斷的改進和對可用治療方案的認知的提高。然而，挑戰包括新藥的嚴格核准流程以及缺乏經核准的生物標記來確認抗治療性。目前正在對潛在的生物學機制進行大量研究，以開發更有效的標靶治療。此外，將心理社會干預措施和數位技術與藥物治療相結合的努力為市場相關人員提供了利潤豐厚的機會。

本研究的主要特點

該報告對全球抗治療性憂鬱症市場進行了詳細分析，包括以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，了解全球抗治療性憂鬱症市場的主要企業概況。
該報告的見解將幫助負責人和公司經營團隊就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球抗治療性憂鬱症市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

公司簡介
- Eli Lilly and Company.
- GlaxoSmithKline
- Pfizer Inc.
- Janssen Pharmaceuticals
- AbbVie Inc.
- AstraZeneca
- H. Lundbeck A/S
- Sandoz International GmbH
- Par Pharmaceutical Companies Inc.
- Otsuka Holdings Co., Ltd.
- Wyeth
- Scherinhg Plough CorporatioN
- Vistagen therapeutics, Inc
- Forest Laboratories
- Bristol-Myers Squibb Company
- Takeda Pharmaceuticals
- Lundbeck
- Allergan
- Supernus Pharmaceuticals
- Sage Therapeutics
- Neuralstem

第9章分析師建議

命運之輪
分析師觀點
Coherent Opportunity Map

第10章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI5196

The Treatment Resistant Depression Market is estimated to be valued at USD 1.91 billion in 2024 and is expected to reach USD 2.54 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.

Figure 1. Treatment Resistant Depression Market Share (%), By Region, 2024

Treatment Resistant Depression Market - IMG1

Treatment resistant depression (TRD) is a widespread mental health condition wherein patients do not respond adequately to standard antidepressant medications. TRD affects approximately 30% to 50% of patients with major depressive disorder. The exact causes that lead to treatment resistance are still unclear but it is believed to involve biological factors like genetics and neurological changes as well as environmental contributors. Patients suffering from TRD experience more severe symptoms of depression like feelings of worthlessness, extreme sadness, fatigue and loss of interest in daily activities with an impaired quality of life. If left untreated, TRD can lead to increased disability, functional impairment and risk of suicide. The treatment resistant depression market comprises therapies aimed at providing alternative treatment options to patients who do not get the desired response from antidepressants.

Market Dynamics:

The global treatment resistant depression market growth is driven by the growing prevalence of TRD worldwide. It is estimated that over 30% of patients suffering from major depression do not achieve remission with first-line antidepressant therapy. This non-responsiveness leads to prolonged suffering and increased economic burden. The market also benefits from improved diagnosis of TRD and widespread awareness about available treatment options. However, factors such as stringent regulatory approval processes for new drugs and lack of approved biomarkers for confirming treatment resistance pose challenges. Significant research into the underlying biological mechanisms is underway to develop more effective targeted therapies. Moreover, initiatives to integrate psychosocial interventions and digital technologies with pharmacotherapy provide lucrative opportunities for market players.

Key features of the study:

This report provides in-depth analysis of the global treatment resistant depression market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global treatment resistant depression market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson & Johnson, Pfizer, GlaxoSmithKline, Merck, LivaNova, Sanofi, Medtronic, Boston Scientific, Brainsway and Nevro
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global treatment resistant depression market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

By Product Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors
- Serotonin-norepinephrine Reuptake Inhibitors
- Others
- Atypical agents
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Eli Lilly and Company
- GlaxoSmithKline
- Pfizer Inc.
- Janssen Pharmaceuticals
- AbbVie Inc.
- AstraZeneca
- Lundbeck A/S
- Sandoz International GmbH
- Par Pharmaceutical Companies Inc.
- Otsuka Holdings Co., Ltd.
- Wyeth
- Scherinhg Plough CorporatioN
- Vistagen therapeutics, Inc
- Forest Laboratories
- Bristol-Myers Squibb Company
- Takeda Pharmaceuticals
- Lundbeck
- Allergan
- Supernus Pharmaceuticals
- Sage Therapeutics
- Neuralstem

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Treatment Resistant Depression Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Treatment Resistant Depression Market, By Drug Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Antidepressants
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Atypical agents
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Treatment Resistant Depression Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Treatment Resistant Depression Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.S.
- Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- GCC
- Israel
- Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
- North Africa
- Central Africa
- South Africa

8. Competitive Landscape

Company Profiles
- Eli Lilly and Company.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- GlaxoSmithKline
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Janssen Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AstraZeneca
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- H. Lundbeck A/S
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sandoz International GmbH
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Par Pharmaceutical Companies Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Otsuka Holdings Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Wyeth
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Scherinhg Plough CorporatioN
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Vistagen therapeutics, Inc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Forest Laboratories
- Bristol-Myers Squibb Company
- Takeda Pharmaceuticals
- Lundbeck
- Allergan
- Supernus Pharmaceuticals
- Sage Therapeutics
- Neuralstem